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WNK1 [with no lysine (K)] and WNK4 regulate blood pressure
by controlling the activity of ion co-transporters in the kidney.
Groundbreaking work has revealed that the ubiquitylation and
hence levels of WNK isoforms are controlled by a Cullin-
RING E3 ubiquitin ligase complex (CRL3KLHL3) that utilizes
CUL3 (Cullin3) and its substrate adaptor, KLHL3 (Kelch-like
protein 3). Loss-of-function mutations in either CUL3 or KLHL3
cause the hereditary high blood pressure disease Gordon’s
syndrome by stabilizing WNK isoforms. KLHL3 binds to a
highly conserved degron motif located within the C-terminal non-
catalytic domain of WNK isoforms. This interaction is essential
for ubiquitylation by CRL3KLHL3 and disease-causing mutations
in WNK4 and KLHL3 exert their effects on blood pressure by
disrupting this interaction. In the present study, we report on the
crystal structure of the KLHL3 Kelch domain in complex with
the WNK4 degron motif. This reveals an intricate web
of interactions between conserved residues on the surface of
the Kelch domain β-propeller and the WNK4 degron motif.
Importantly, many of the disease-causing mutations inhibit
binding by disrupting critical interface contacts. We also present
the structure of the WNK4 degron motif in complex with KLHL2
that has also been reported to bind WNK4. This confirms that
KLHL2 interacts with WNK kinases in a similar manner to
KLHL3, but strikingly different to how another KLHL protein,
KEAP1 (Kelch-like enoyl-CoA hydratase-associated protein 1),
binds to its substrate NRF2 (nuclear factor-erythroid 2-related
factor 2). The present study provides further insights into
how Kelch-like adaptor proteins recognize their substrates and
provides a structural basis for how mutations in WNK4 and
KLHL3 lead to hypertension.
Key words: Bric-a-brac, Tramtrack, and Broad complex (BTB
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INTRODUCTION
The WNK [with no lysine (K)] kinases play central roles in
regulating mammalian blood pressure by initiating a signalling
pathway that controls the activity of critical ion co-transporters
in the kidney NCC (Na+ /Cl− ion co-transporter) and NKCC2
(Na+ /K+ /2Cl− co-transporter 2) [1–3]. There are four widely
expressed mammalian WNK isoforms (WNK1, WNK2, WNK3
and WNK4) that exert their physiological effects by activating
two highly related protein kinases termed SPAK [SPS1-related
proline/alanine-rich kinase; also known as STK39 (serine
threonine kinase 39)] and OSR1 (oxidative stress-responsive
kinase 1) [1,4–10]. Once activated, SPAK/OSR1 promote salt
retention by phosphorylating and activating sodium ion co-
transporters (NKCC1, NKCC2 and NCC) [1,4,6–9,11,12] and
inhibiting KCCs (potassium ion co-transporters) [1,13].
The importance of the WNK system in controlling blood
pressure was first illustrated by the finding that intronic
mutations within the human WNK1 gene that increase WNK1
mRNA expression, and presumably WNK1 protein expression,
result in Gordon’s hypertension syndrome (also known as
pseudohypoaldosteronism type II) [3,10,14]. Mutations within
a non-catalytic highly acidic motif of WNK4 located C-terminal
to the kinase domain (residues 557–567) also cause Gordon’s
syndrome [10,15]. How mutations within this region, which is
conserved in all WNK isoforms, stimulated the WNK signalling
system was not clear. However, findings from previous studies
suggest that this acidic region plays a critical role in controlling
the ubiquitylation, and hence stability of WNK4, by operating as a
degron motif for the CRL3KLHL3 E3 ligase complex, which includes
CUL3 (Cullin3) and the substrate adaptor KLHL3 (Kelch-like
protein 3) [4–9]. The current data point towards a model in which
the CRL3KLHL3 complex binds to the acidic degron motif leading
to WNK4 ubiquitylation and proteasomal degradation. This
conclusion is supported by the finding that mutations in KLHL3
that inhibit binding to either CUL3 or WNK4 also cause Gordon’s
hypertension syndrome in humans [1,4,6–9,11,12]. Moreover,
in vitro, the CRL3KLHL3 complex efficiently ubiquitylates WNK1
and WNK4 in a manner that is prevented by the most commonly
described KLHL3 mutation (R528H) [6]. Consistent with the
acidic region operating as a degron motif, recent work has revealed
that a WNK4 knock-in mouse displaying a Gordon’s syndrome
mutation within this motif (WNK4 [D561A]) possesses markedly
elevated levels of WNK4 in the kidney [7]. Furthermore, the
D561A mutation decreased WNK4 ubiquitylation by CRL3KLHL3
in an overexpression system [7]. These studies emphasize the
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importance that the interaction between the KLHL3 and acidic
degron motif play in controlling the ubiquitylation and stability
of WNK isoforms and therefore blood pressure.
CUL3 acts as a scaffolding protein that, through its N-
terminus, binds to the BTB (Bric-a-brac, Tramtrack, and Broad
complex) domain in KLHL3 [16]. KLHL3 is the substrate-
recognition subunit of the ubiquitin ligase complex, recruiting
substrates for ubiquitylation via its associated Kelch domain
[17–19]. The CUL3 C-terminus also interacts with the RING-
finger protein RBX1 (ring-box 1), which binds to ubiquitin-
charged E2 enzymes and promotes transfer of ubiquitin
on to the bound substrate [20]. In addition to KLHL3,
CUL3 can form distinct E3 ligase complexes with other
BTB-domain-containing proteins [21,22]. There are close to
200 BTB domain proteins encoded in the human genome,
and although thus far only 11 BTB adaptor subunits have
been well characterized in humans, there are likely to be
numerous more CUL3 adaptor complexes that interact with
many diverse substrates [19]. For example, CUL3 interacts
with the BTB-Kelch-like protein KEAP1 (Kelch-like enoyl-CoA
hydratase-associated protein 1), which binds to and ubiquitylates
the transcription factor NRF2 (nuclear factor-erythroid 2-related
factor 2) [23]. Dimerization of the BTB domain affords two Kelch
domains per CUL3 adaptor. In this instance, NRF2 possesses one
high affinity degron and a second lower-affinity degron-binding
site. Both sites need to be engaged by two Kelch domains of
dimeric KEAP1 to appropriately orient NRF2 for ubiquitylation
[24]. Another member of the BTB-Kelch family of proteins is
KLHL2 (also known as Mayven). KLHL2 shares 84% sequence
identity with KLHL3 across the Kelch domain, and 86% identity
overall (see Figure 2A). KLHL2 has also been implicated recently
as a CUL3 substrate adaptor for WNK kinases [25].
In the present study, we scrutinize the interaction between the
WNK degron motif and KLHL3 as well as KLHL2. The data
reveal the fundamental features of this interaction and explain
how several of the disease-causing mutations disrupt binding. Our
results also reveal that the WNK degron motif binds to KLHL3 in
a markedly different manner to how NRF2 binds to KEAP1,
which is the only other BTB-Kelch protein for which substrate
interactions have been analysed at the structural level thus far.
MATERIALS AND METHODS
Materials
Lumio Green, Colloidal Blue staining kit and precast SDS
polyacrylamide BisTris gels were from Invitrogen. All peptides
were synthesized by GL Biochem to a purity of >95%; peptide
sequences were determined by MS.
Plasmids
The full-length coding region of KLHL3 (NM_017415.2) was
amplified from skeletal muscle total RNA (Agilent) by using RT-
PCR (reverse transcription–PCR) according to the manufacturer’s
protocol (SuperScript® III One Step RT-PCR, Invitrogen).
Fragments of KLHL3 comprising residues 290–587 and 296–
587 were subsequently PCR-amplified adding flanking BglII and
NotI restriction and shuttled directly into the bacterial expression
vector pGEX6P-1 downstream of GST and a PreScission
Protease cleavage site. Point mutations were introduced using
the QuikChange® method (Stratagene) in conjunction with KOD
Hot Start DNA polymerase (Novagen). KEAP1 (NM_203500.1)
was amplified from EST IMAGE 3163902 and subcloned as
a BamHI/NotI insert into a modified pFastbacDualbaculoviral
vector containing an N-terminal DAC tag [26] with a TEV
(tobacco etch virus) protease site downstream of the DAC
tag. DNA sequencing was performed by The Sequencing
Service, College of Life Sciences, University of Dundee, U.K.
(www.dnaseq.co.uk).
For structure determination, human KLHL2 (IMAGE clone
4791972; residues 294–593) and human KLHL3 (NM_017415.2;
residues 298–587) were cloned into the expression vector
pNIC28-Bsa4 (GenBank® accession number EF198106) by
ligation-independent cloning. This vector encodes for an N-
terminal His6 tag and rTEV (recombinant TEV) cleavage site.
General methods
Restriction enzyme digests, DNA ligations and other DNA
procedures, were performed using standard protocols. Site-
specific mutagenesis was achieved using the standard
QuikChange® method (Stratagene).
Protein purification for fluorescent polarization
All pGEX-6P-1 constructs were transformed into BL21
Escherichia coli cells, and 2 litre cultures were grown at 37 ◦C in
LB broth containing 100 μg/ml ampicillin until the D600 reached
0.6. IPTG was then added (50 μM) and the cells were cultured
for a further 16 h at 16 ◦C. Cells were isolated by centrifugation,
resuspended in ice-cold lysis buffer and lysed by sonication. The
lysates were centrifuged at 4 ◦C for 15 min at 26000 g. The GST-
fusion proteins were affinity purified on 0.5 ml of glutathione–
Sepharose and eluted in buffer containing 20 mM glutathione.
KLHL3 full-length protein (residues 1–587) was expressed
and purified as a DAC-(TEV protease)KLHL3 fusion protein
in Sf21 cells as described previously in [6]. KEAP1 full-length
protein (residues 1–624) was expressed as a DAC-(TEV protease)-
KEAP1 fusion protein in insect Sf21 cells [26]. The fusion
protein was purified by capture on ampicillin–Sepharose followed
by treatment with TEV protease to release KEAP1 and further
purification was achieved by size-exclusion chromatography (S75
Superose; GE Healthcare).
Fluorescence polarization
Fluorescence polarization measurements were performed at
25 ◦C with purified KLHL3 proteins in 50 mM Tris/HCl,
pH 7.5, 150 mM NaCl and 2 mM DTT. The concentration
of the KLHL3 proteins, KLHL3, GST–KLHL3290 − 587, KEAP1
and GST–KLHL2296 − 593, was determined by measuring their
absorbance at 280 nm and calculated using the molar absorption
coefficient determined by the ProtParam Online tool [27]. All
peptides contained an N-terminal linker required for conjugating
to the Lumio Green fluorophore (CCPGCCGGGG) and were
initially resuspended in 50 mM ammonium biocarbonate, pH 8.
Peptide labelling was achieved by incubating 10 nM of each
peptide in a 0.5 ml reaction mixture of 20 μM Lumio Green
in 50 mM Tris/HCl, pH 7.5, 150 mM NaCl and 2 mM DTT.
Reactions were left to proceed in the dark for 2 h. The peptides
were then dialysed for 16 h into 50 mM Tris/HCl, pH 7.5, 150 mM
NaCl and 2 mM DTT using a Micro DispoDIALYZER with a 100
Da molecular-mass cut-off (Harvard Apparatus). For fluorescence
polarization, mixtures were set up containing the indicated
concentration of protein, 10 nM Lumio-Green-labelled peptide in
a final volume of 30 μl. All individual bindings were performed
in duplicate with at least 12 data points per curve. Fluorescence
polarization measures were made using a BMG PheraStar plate
reader, with an excitation wavelength of 485 nm and an emission
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Characterization of KLHL3–WNK kinase binding 239
wavelength of 538 nm, and measurements were corrected to the
fluorescent probe alone. Data analysis and graphing were then
performed in GraphPad Prism6; One Site Specific binding with
Hill slope was assumed (model Y = Bmax×Xh/Kdh + Xh) and the
disassociation constant and associated S.E.M. was obtained. All
experimental bindings were repeated a minimum of two times
and comparable results to those shown in the present study were
obtained.
Protein expression and purification for crystallization
For structure determination, human KLHL2 (residues 294–
593) and KLHL3 (residues 298–587) were expressed from the
vector pNIC28-Bsa4 in BL21(DE3)-R3-pRARE cells (a phage-
resistant derivative of Rosetta2, Novagen). Cultures (1 litre) in
Terrific broth were incubated at 37 ◦C until D600 reached 2.0 and
then cooled to 18 ◦C and supplemented with 0.5 mM IPTG to
induce protein expression overnight. Cells were harvested by
centrifugation, resuspended in binding buffer {50 mM Hepes,
pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol and
0.5 mM TCEP [tris-(2-carboxyethyl)phosphine]} and lysed by
sonication. The His6-tagged proteins were purified using Ni2 + –
Sepharose resin (GE Healthcare) and eluted stepwise in binding
buffer with 100–250 mM imidazole. Removal of the His6 tag
was performed at 4 ◦C overnight using rTEV protease. Proteins
were then further purified by anion exchange chromatography
using a 5 ml HiTrap SP (KLHL2) or a 5 ml HiTrap Q (KLHL3)
column (GE Healthcare), followed by buffer-exchange into
50 mM Hepes, pH 7.5, 300 mM NaCl, 5% glycerol and 0.5 mM
TCEP using size-exclusion chromatography (Superdex 200 16/60,
GE Healthcare).
Crystallization and data collection
The purified proteins were concentrated to 9 mg/ml using
a 10 kDa molecular-mass cut-off centrifugal concentrator
(Millipore). The 11-residue WNK4 peptide (EPEEPEADQHQ)
was added to a final concentration of 2 mM. The protein–peptide
solution was incubated on ice for approximately 30 min before
preparation of sitting-drop vapour-diffusion crystallization plates.
Crystals grew under multiple conditions using either freshly
prepared or frozen protein. The best-diffracting crystals of the
KLHL2 complex were obtained at 20 ◦C by mixing 100 nl
of protein with 50 nl of a reservoir solution containing 0.1 M
Hepes, pH 7.2, 2.5 M ammonium sulfate and 2% PEG 400.
Crystals of the KLHL3 complex were grown similarly using
0.1 M acetate, pH 4.3, 0.2 M ammonium sulfate and 25–35%
PEG 4000. After 3 h of incubation, the drops were spiked with 20
nl of seed-stock solution. Seed stock was prepared from poorly
formed crystals of KLHL2 or KLHL3 grown during previous
rounds of crystal optimization, which were transferred into an
Eppendorf containing 50–100 μl of reservoir solution and a seed
bead (Hampton Research), then vortex-mixed for 2 min. Before
vitrification in liquid nitrogen, crystals were cryoprotected by
direct addition of reservoir solution supplemented with 25%
ethylene glycol. Diffraction data were collected on beamline I02
at Diamond Light Source, Didcot, U.K.
Structure determination
Diffraction data for both the KLHL2 and KLHL3 crystals were
integrated using Mosflm [28] and scaled using SCALA [29]
from the CCP4 software suite [30]. Molecular replacement was
performed with Phaser MR in CCP4 using PDB code 2XN4
chain A (apo Kelch domain of KLHL2) as the search model.
COOT [31] was used for manual model building and refinement,
whereas REFMAC [32] and PHENIX.REFINE [33] were used
for automated refinement. TLS (Translation–Libration–Screw-
rotation) parameters were included at later stages of refinement.
Tools in COOT, PHENIX and MolProbity [34] were used to
validate the structures. Structure factors and co-ordinates have
been deposited in the PDB under 4CHB (KLHL2) and 4CH9
(KLHL3).
RESULTS
Defining the KLHL3-binding residues within the WNK4 acidic
degron motif
As outlined in the Introduction, previous work highlighted that
residues within the WNK4 acidic degron motif play a critical role
in binding to KLHL3 [4,6–9]. To confirm these data and to set up
a quantitative binding assay to monitor the interaction of KLHL3
with the motif, we expressed and purified either full-length
KLHL3 or the isolated C-terminal Kelch domain (residues 290–
587) and used fluorescence polarization to study the interaction of
a 19-residue peptide encompassing the conserved acidic degron of
WNK4 (residues 549–567: GPPSVFPPEPEEPEADQHQ). This
revealed that full-length KLHL3, as well as the isolated KLHL3
Kelch domain, bound to the 19-residue WNK4 peptide with high
affinity (Kd = 0.3–0.9 μM) (Figure 1A and Table 1). Replacement
of KLHL3 Gordon’s syndrome-causing mutations located within
the Kelch domain (R528H or N529K) reduced binding to the
WNK4 degron peptide approximately 10-fold (Figure 1B and
Table 1). Introduction of D564A or Q565E disease-causing
mutations within the WNK4 degron similarly resulted in a 10-
fold reduction in binding, whereas the E562K mutation virtually
abolished binding (Figure 1C and Table 1).
We went on to study the impact of truncating N- and C-terminal
residues of the 19-residue WNK4 peptide to further characterize
the WNK degron required for KLHL3 recognition. This revealed
that removal of eight N-terminal residues (GPPSVFPP) had no
appreciable effect on KLHL3 binding (Figure 1D and Table 1).
However, removal of even just one C-terminal residue markedly
reduced binding. All subsequent studies were therefore performed
using the core 11-residue WNK4 peptide (EPEEPEADQHQ) that
binds KLHL3 with high affinity (Kd = 0.69 μM). Interestingly,
this sequence is identical in WNK1 and WNK4, whereas
four of the 11 residues differ in WNK3 (Figure 1E). We
therefore investigated whether these substitutions in WNK3
(ECEETEVDQHV, where bold and underlined residues differ
to WNK1/4 degron motifs) were compatible with high-affinity
binding to KLHL3. We observed that despite these sequence
differences, the WNK3 motif interacted with KLHL3 with
similarly high affinity to WNK1/4 (Figure 1F and Table 1). We
also found that the NRF2 degron motif bound strongly to KEAP1,
but not to KLHL3 (Figure 1F and Table 1). Vice versa, the
WNK1/4 degron failed to bind KEAP1 (Figure 1F and Table 1),
confirming the selectivity of these substrate adaptor proteins.
Structure determination of the WNK1/4 acidic degron motif bound
to KLHL3 and KLHL2
The KLHL3 residues that are mutated in Gordon’s syndrome
are widely distributed across the Kelch domain of KLHL3
(Figure 2A). These residues are also strictly conserved in the
highly homologous KLHL2 protein (Figure 2B) that has also been
reported to bind WNK4 [25]. Consistent with this, we found that
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Figure 1 Analysis of KLHL3–WNK interaction by fluorescence polarization
(A–D and F) Purified KLHL3 was diluted appropriately and mixed at a 1:1 volume ratio with 20 nM Lumino-Green-labelled WNK peptide to the concentration stated in the Figure, with the
peptide concentration consistent at 10 nM, and fluorescent polarization measurements were made. Binding curves, assuming one-site-specific binding, were then generated with Prism6 using
milli-polarization (mP) units. The determined dissociation constant for each binding experiment is shown in Table 1. The purified KLHL3 proteins used in the binding experiments were analysed on
SDS/PAGE and are shown in panels to the right of the binding curve. Molecular masses are indicated on the left of the gels. (A) Comparison of full-length KLHL3 and the isolated Kelch-domain of
KLHL3 binding to the 19-residue WNK4 degron peptide (GPPSVFPPEPEEPEADQHQ, residues 549–567). (B) Influence of KLHL3 Gordon’s syndrome mutations on WNK4 peptide binding. Purified
GST-KLHL3290 − 587 wild-type, or the point mutants, GST–KLHL3290 − 587 R528H, GST–KLHL3290 − 587 N259K, were analysed for their ability to bind the 19-residue WNK4 degron peptide. (C) Effect
of WNK4 Gordon’s syndrome mutations on KLHL3 binding. Purified GST–KLHL3290 − 587 wild-type protein was mixed with the 19-residue wild-type (WT) or indicated point mutants (E562K, D564A
and Q565E) of the WNK4 degron peptide. The sequences of all peptides used are shown in the bottom panel exclude the N-terminal sequence (CCPGCCGGGG) required for Lumio Green labelling.
(D) Impact of shortening the WNK4 peptide on KLHL3 binding. The ability of the indicated WNK4 peptides A–F (the sequences of which are shown below the binding curve) to bind purified
GST–KLHL3290 − 587 protein was evaluated. (E) Location and conservation of degron motif in WNK isoforms. The upper panel displays the domain organisation of WNK isoforms and the location of
the degron motif within the C-terminal non-catalytic domain. The lower panel displays an alignment of the degron motif in different WNK isoforms with that of the previously characterized degron
motif of the NRF2 transcription factor that interacts with the KEAP1 Kelch-like protein [38]. Identical residues are shaded in black. (F) Evaluation of the ability of WNK1/4, WNK3 and NRF2 degron
peptides to interact with GST–KLHL3290 − 587 (open symbols) and full-length KEAP1 (closed symbols). WT, wild-type.
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Table 1 Disassociation constants (K d) for peptides binding to different Kelch-like proteins
K d values calculated from the different fluorescence polarization binding studies shown in Figures 1 and 2. The Kelch-domain protein construct, peptide sequence and calculated K d values for each
experiment are indicated. All peptide sequences shown exclude the N-terminal sequence (CCPGCCGGGG) that was required for Lumio Green labelling and was present on all peptides listed in this
Table. One site-specific binding with Hill slope was assumed and the disassociation constant (K d), determined in Prism6 using the curves generated and shown in the associated Figures, is noted,
along with the S.E.M. Peptides for which binding was too low to measure accurately (K d>50 μM) are marked LB (low binding). WT, wild-type.
Figure Kelch protein Peptide sequence K d (μM)
1(A) KLHL3 full-length GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 0.62 +− 0.04
GST–KLHL3290–587 GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 0.38 +− 0.03
1(B) GST–KLHL3290–587 GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 0.19 +− 0.01
GST–KLHL3290–587R528H GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 1.93 +− 0.15
GST–KLHL3290–587N529K GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 6.60 +− 1.02
1(C) GST–KLHL3290–587 GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 0.48 +− 0.03
GST–KLHL3290–587 GPPSVFPPEPEEPKADQHQ (WNK4 E562K 549–567) LB
GST–KLHL3290–587 GPPSVFPPEPEEPEAAQHQ (WNK4 D564A 549–567) LB
GST–KLHL3290–587 GPPSVFPPEPEEPEADEHQ (WNK4 Q565E 549–567) 6.21 +− 1.02
1(D) GST–KLHL3290–587 GPPSVFPPEPEEPEADQHQ (WNK4 WT 549–567) 0.90 +− 0.06
GST–KLHL3290–587 FPPEPEEPEADQHQ (WNK4 WT 554–567) 0.71 +− 0.05
GST–KLHL3290–587 PPEPEEPEADQHQ (WNK4 WT 555–567) 0.91 +− 0.06
GST–KLHL3290–587 PEPEEPEADQHQ (WNK4 WT 556–567) 0.29 +− 0.05
GST–KLHL3290–587 EPEEPEADQHQ (WNK4 WT 557–567) 0.69 +− 0.04
GST–KLHL3290–587 FPPEPEEPEADQH (WNK4 WT 554–566) 7.81 +− 0.48
GST–KLHL3290–587 FPPEPEEPEAD (WNK4 WT 554–564) LB
1(F) GST–KLHL3290–587 EPEEPEADQHQ (WNK4 WT 557–567 0.35 +− 0.04
GST–KLHL3290–587 ECEETEVDQHV (WNK3 WT 537–547) 0.84 +− 0.05
GST–KLHL3290–587 LQLDEETGEFL (NRF2 WT 74–84) LB
KEAP1 full-length EPEEPEADQHQ (WNK4 WT 557–567 LB
KEAP1 full-length ECEETEVDQHV (WNK3 WT 537–547) LB
KEAP1 full-length LQLDEETGEFL (NRF2 WT 74–84) 0.44 +− 0.01
2(C) GST–KLHL3290–587 EPEEPEADQHQ (WNK4 WT 557–567) 0.51 +− 0.02
GST–KLHL2298–593 EPEEPEADQHQ (WNK4 WT 557–567) 0.26 +− 0.01
the WNK1/4 degron motif bound to the Kelch domain of KLHL2
with similar affinity to KLHL3 (Figure 2C). In contrast, most of
the disease-causing mutations in KLHL3 are not conserved in the
Kelch domain of KEAP1 (Figure 2B).
We determined the high-resolution crystal structures of the
Kelch domains of human KLHL3 and KLHL2 in separate
complexes with the 11-residue WNK4 degron motif (Figure 2D).
Two Kelch domains were found in the asymmetric unit of
each structure. The KLHL2 structure was solved at 1.6 Å
(1 Å = 0.1 nm) resolution in space group P43212, whereas the
structure of KLHL3 was determined at 1.8 Å in space group
P212121. Data processing and refinement statistics for both
structures are presented in Table 2. Electron density for the WNK4
peptide was clearly visible in both structures after initial molecular
replacement and after refinement, the peptide was modelled into
the binding site as shown in Figure 2(D) and Figure 3. For the
KLHL2 structure, residues 292–305 from the N-terminus and
residues 592–593 from the C-terminus were not clearly resolved
in the electron density and were excluded from the model, as was
the C-terminal residue of the WNK4 peptide (Gln567). Similarly,
residues 296–299 and 586–587 of KLHL3 could not be modelled
into the KLHL3–WNK4 complex, and WNK4 residues 566–567
and the side chains of Glu559 and Glu560 were also not defined
(Figure 3A). The KLHL2 and KLHL3 structures were determined
at pH 7.5 and pH 4.3 respectively, which probably contributes to
differences in the resolution of particular residues. For example,
protonation of WNK4 His566 may explain why this residue is not
clearly resolved in the crystal structure of the KLHL3 complex.
WNK4 Gln567 was disordered in both structures, consistent with
a lack of stabilizing side-chain contacts, yet was critical for
peptide binding (Figure 1D and Table 1). Although side-chain
substitutions were tolerated at this position (for example, Val547 in
WNK3), truncations were likely disfavoured by the introduction
of an undesirable C-terminal carboxy group, or by changes
induced in the conformation of the peptide backbone.
The overall β-propeller structure of the Kelch domain from
the BTB-Kelch family has been well described [17,35–38]. Six
Kelch repeats, each composed of four antiparallel β-strands,
form the six blades of the barrel structure. The final strand at
the C-terminus pairs with the N-terminal strand to complete
blade I (Figure 2D). In the present study, we show that KLHL3
and KLHL2 are structurally highly similar (Cα RMSD of
0.6 Å), and that both Kelch domains share a common mode
of interaction with WNK4/1 peptide (Supplementary Figure
S1A at http://www.biochemj.org/bj/460/bj4600237add.htm).
Comparison of these structures with the KLHL2 apo (unbound)
structure determined previously (PDB code 2XN4), reveals
only minor conformational differences (Supplementary Figure
S1B). This suggests that the KLHL3-binding site for WNK4 is
essentially rigid and conserved across both proteins.
Gordon’s syndrome mutations affect key residues in the
KLHL3–WNK4 interface
Owing to the high level of similarity between the KLHL2–
WNK4 and KLHL3–WNK4 structures, all remaining discussion
focuses on the KLHL3 structure. The binding interface between
KLHL3 and WNK4 spans all six Kelch repeats and has a
total buried surface area of 510 Å2, with blades II, III and IV
participating in the greatest number of contacts (Figure 3B).
Numerous contacts between KLHL3 and the WNK4 peptide can
be observed, and together these interactions facilitate high-affinity
binding between these two proteins. A number of KLHL3 residues
provide significant hydrophobic contact with WNK4; including
Phe355, Phe402, Gly404, Tyr449, Gly451 and His498 (Figure 3C). Among
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Figure 2 Overview of the KLHL2 and KLHL3 structures and their interaction with the WNK degron motif
(A) Schematic representation of the Kelch domain (residues 302–585) of KLHL3 with the positions of the dominant Gordon’s syndrome-associated mutations illustrated. (B) Sequence alignment of
the Kelch domain of KLHL2, KLHL3 and KEAP1, with the secondary structure of KLHL3 indicated. A black star above the amino acid indicates the position of a Gordon’s syndrome mutation and a
grey triangle indicates key contact residues in the KLHL3–WNK4 structure. (C) Comparison of the binding of the WNK4 degron motif to KLHL2 and KLHL3. Fluorescent polarisation measurements
were made as described in Figure 1 and the Materials and methods section. Purified GST–KLHL3290 − 587 or GST–KLHL2298 − 593 were mixed with the 11-residue WNK4 (557–567) degron peptide
and binding curves were generated. (D) An overview of the KLHL2–WNK4 (top panel) and KLHL3–WNK4 (bottom panel) crystal structures. The Kelch domain is shown in cartoon representation and
the WNK4 peptide is shown in purple stick representation.
the KLHL3 residues, Arg360 contributes the greatest contact area
and forms hydrogen bond interactions with WNK4 Glu557, as
well as with the main chain atoms of WNK4 Pro558 and Glu560.
KLHL3 Arg339 also forms a hydrogen bond with the main-chain
carbonyl of WNK4 Glu559. Other important polar interactions
involve residues that are mutated in some instances of Gordon’s
syndrome (Figure 3D). For example, WNK4 Glu562 has the
greatest contact area of any interface residue and protrudes into
the cleft between blades III and IV to hydrogen bond with
KLHL3 Ser432 (Figure 3D, right-hand panel). Mutations have
been described at both sites in patients with Gordon’s syndrome
(E562K and S432N respectively) [11,39] and would probably
introduce steric clashes, as well the loss of hydrogen-bond
formation. Perhaps the most notable interaction is the salt bridge
formed between KLHL3 Arg528 and WNK4 Asp564 (Figure 3D,
middle panel). Patients with Gordon’s syndrome have been
identified with mutations in either of these residues and notably
mutation of Arg528 to a histidine residue is the most prevalent
KLHL3 mutation described thus far. A histidine side chain at this
position would potentially disrupt the local structure in KLHL3
and would be too short to maintain a hydrogen-bond interaction
with WNK4. The WNK4 D564A mutation would similarly disrupt
this interaction and indeed our independent binding experiments
using either KLHL3 R528H or WNK4 D564A (Figures 1B
and 1C) confirm the importance of this salt bridge for a high-
affinity interaction. Finally, a buried water molecule is observed
to mediate hydrogen bonding between WNK4 Ala563 and the
side chains of KLHL3 Ser432 and Ser433 (Figure 3D, right-hand
panel). Gordon’s syndrome mutations at either position (S432N
or S433N) would disrupt this interaction network.
Other Gordon’s syndrome mutations in KLHL3, including
Q309R and N529K, are not involved in direct contact between the
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Figure 3 Interactions in the KLHL3–WNK4 complex
(A) The conformation of the WNK4 11-mer peptide and corresponding electron density contoured at 1.0 σ for the KLHL3–WNK4 structure (PDB code 4CH9). (B) Buried surface area graphs for
contact residues in the KLHL3–WNK4 complex. A black star indicates residues that are mutated in Gordon’s syndrome. (C) An overview of the key WNK4-interacting residues (left-hand panel) and
important polar contacts (right-hand panel) in the KLHL3–WNK4 interaction. KLHL3 is shown in light blue and WNK4 peptide in yellow. (D) The relative position of Gordon’s syndrome-associated
mutations found in KLHL3 (left-hand panel). Mutations R528H in KLHL3 (middle panel) and E562K in WNK4 (right-hand panel) affect residues with the highest buried surface area in each protein.
The mutated residues are indicated in pink, with non-mutated residues in light blue (KLHL3) or yellow (WNK4). Dotted lines indicate hydrogen-bonding interactions. A bridging water molecule,
between KLHL3 Ser433 and WNK4 Ala562 is indicated by a red sphere.
two proteins, but are situated within close proximity to the peptide-
binding site (Figure 3D). These substitutions most likely disrupt
the interaction by unfavourably altering the shape and charge
of the binding pocket and by perturbing neighbouring residues
in the binding interface. For example, the N529K mutation is
predicted to perturb both the salt bridge between KLHL3 Arg528
and WNK4 Asp564, and the van der Waals packing interactions
of KLHL3 Tyr577. The importance of KLHL3 Asn529 for WNK4
binding is demonstrated by the decreased affinity of the WNK4
19-residue peptide for KLHL3 N529K relative to wild-type
KLHL3 (Figure 1B).
The remaining mutations identified in the Kelch domain of
KLHL3 (A340V, R384Q, L397P, S410L and A494T) lie in
sites disparate from the binding area. Arg384 and Ser410 form
an intramolecular hydrogen bond between blades II and III
that would be lost upon mutation, whereas A340V, L387P and
A494T affect residues buried in the wild-type structure. All
of these mutations are predicted to have a negative impact
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Table 2 Crystallographic data collection and refinement statistics
Relevant crystallographic statistics for the structures of KLHL2 and KLHL3 with WNK4 peptide
(PDB codes 4CHB and 4CH9 respectively). Values in parentheses indicates data for the highest
resolution shell. ASU, asymmetric unit.
Parameter KLHL2–WNK4 peptide KLHL3–WNK4 peptide
Data collection
Space group P43212 P212121
Cell constants
a, b, c (A˚) 117.7, 117.7, 106.65 84.76, 45.33, 146.79
α, β , γ (◦) 90, 90, 90 90, 90, 90
Resolution (A˚) 39.52–1.52 (1.57–1.52) 73.40–1.84 (1.90–1.84)
Unique observations 114962 (11326) 49110 (4342)
Completeness (%) 99.9 (39.52–1.56 A˚) 98.0 (73.40–1.84 A˚)
Redundancy 7.6 (7.0) 4.4 (3.0)
Rmerge 0.14 (1.1) 0.06 (0.25)
I/σ I 1.94 (at 1.52 A˚) 3.58 (at 1.84 A˚)
Refinement
Resolution (A˚) 39.52–1.56 73.40–1.84
MR model 2XN4 2XN4
Copies in ASU 2 2
Rwork/R free 0.177/0.194 0.144/0.184
Number of atoms 4998 5096
Average B-factor (A˚2) 15.0 17.0
Average B-factor (protein) (A˚2) 14.9 15.5
Average B-factor (peptides) (A˚2) 27.3 33.9
Average B-factor (solvent) (A˚2) 24.1 28.9
RMSD (bonds) (A˚) 0.07 0.01
RMSD (angles) (◦) 1.04 1.18
PDB code 4CHB 4CH9
on the overall tertiary structure and stability of the KLHL3
protein.
DISCUSSION
The highlight of the present study is that it defines the binding
between the acidic degron motif of the WNK kinases and KLHL3
and KLHL2. This provides a molecular mechanism for the capture
of these kinases by the CRL3KLHL3 and CRL3KLHL2 ubiquitin ligase
complexes. Furthermore, it offers a structural explanation for the
disruptive effects of a number of Gordon’s syndrome mutations
that are described in WNK4 and the Kelch domain of KLHL3.
These mutations would inhibit the ubiquitylation of WNK4, and
probably other WNK isoforms, by the CRL3KLHL3 complex,
and result in the cellular accumulation of these master regulators
of blood pressure. This, in turn, would be predicted to lead to
overactivation of SPAK/OSR1 and the NCC/NKCC2 ion co-
transporters, and consequently, increased salt retention leading
to hypertension.
Our data further support the recent finding that KLHL2 may
also function as a second CUL3 adaptor for the WNK kinases [25].
The presented structures reveal that KLHL2 and KLHL3 bind to
the WNK1/4 degron in an almost indistinguishable manner and
maintain strict conservation of all critical contact residues. Thus
far, no mutations in KLHL2 have been described in patients with
Gordon’s syndrome, but the binding data strongly suggest that
KLHL2 will also play a role in regulating WNK isoforms. In future
work, it would be interesting to explore the relative importance of
KLHL3 and KLHL2 for regulation of WNK isoforms, which vary
in their relative abundance within different tissues. KLHL2 is best
known for its high expression in the brain [40], whereas KLHL3
may play a dominant role in the kidney, consistent with the effects
of KLHL3 mutations in hypertension. Sequence comparisons
across the BTB-Kelch family suggest that only KLHL3 and
KLHL2 possess the conserved residues required to interact with
the WNK degron motif [17].
To promote efficient ubiquitylation of NRF2 by the KEAP1–
CUL3 ligase complex (CRL3KEAP1), both a high-affinity and
a low-affinity binding site must be engaged [41]. Given our
peptide-based approach, we did not investigate whether a second
low-affinity binding site is required for WNK ubiquitylation. It
would be interesting to investigate in future studies whether a
second binding site does indeed exist in the WNK isoforms,
and furthermore, whether all Kelch substrates may have a
high- and low-affinity degron site to fine tune substrate capture.
Alternatively, given that WNK isoforms are known to be able
to form both hetero- and homo-dimers [42], these two high-
affinity WNK degrons may be sufficient to engage separately
the two Kelch domains within the KLHL3 dimer. In this model,
WNK dimerization may also influence WNK ubiquitylation
levels.
Our structural and biochemical data suggest that all WNK
isoforms may be regulated by the CRL3KLHL3/CRL3KLHL2
ubiquitin–ligase complexes. We were surprised to find that,
despite the WNK3 degron containing four changes out of 11
residues, it still bound with high affinity to KLHL3 (Figure 1F).
The WNK2 degron contains only one residue change at the C-
terminal position relative to the WNK4/1 degron (Figure 1E).
Although we have not directly tested whether the WNK2 degron
binds to KLHL3, this is likely, as this residue was disordered
in the KLHL3 complex structure and therefore unlikely to make
a significant contribution to binding. The current data therefore
indicate that all WNK isoforms will bind to KLHL3 and KLHL2
with similar affinity, at least in vitro.
In future it will be important to explore how ubiquitylation
of WNK isoforms by CRL3KLHL3 is regulated and whether
differences in the degron motif sequence might have an impact on
the regulation. Notably, there are no phosphorylatable residues
within the WNK1/4 degron, whereas the WNK3 degron does
contain a conserved threonine residue (Thr541 in humans).
Phosphorylation of this threonine residue would be predicted
to disrupt the peptide interactions observed in the crystal
structures and therefore WNK3–KLHL3/2 interactions could
be regulated by phosphorylation. In the case of the KEAP1
system, in non-redox stressed cells, CRL3KEAP1 binds to and
ubiquitylates the transcription factor NRF2, targeting it for
proteasomal degradation [43]. Under conditions of oxidative
stress, cysteine modification of KEAP1 leads to structural
changes that prevent binding to NRF2, thereby inhibiting NRF2
ubiquitylation resulting in its markedly increased expression [44].
By analogy, regulation of WNK ubiquitylation may be controlled
at the level of KLHL2/KLHL3. For example, in future work
it would be instructive to explore whether osmotic conditions,
known to greatly influence the WNK signalling pathway, alter
the ability of KLHL2/KLHL3 to bind to the WNK degron or, to
ubiquitylate WNK isoforms.
To date, structural studies of substrate recognition within
the BTB-Kelch family have been limited to KEAP1, including
complexes with NRF2 [37,38,45], the degron motifs of
prothymosin-α [46] and sequestosome-1 [47]. Overall, these
substrates were bound to KEAP1 in an almost identical position
suggesting a preferred interaction site for Kelch–substrate
interactions. Despite a similar acidic character, the WNK degron
motif binds KLHL2/KLHL3 in a strikingly different manner to
the KEAP1–substrate complexes (Figure 4A). Indeed, WNK4
and NRF2 peptides not only bind at different positions within
the Kelch domain, but they are also orientated opposite to one
another in terms of their N- and C-termini (Figure 4A). The NRF2
peptide makes greatest contact with blades I, IV and V of the
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Figure 4 Comparison of WNK4 and NRF2 binding modes
(A) The KLHL3–WNK4 structure (rainbow cartoon representation) was superimposed with that of the KEAP1–NRF2 complex (PDB code 2FLU) (grey). The WNK4 peptide (purple) is positioned in the
opposite orientation and across different areas of the Kelch domain relative to the NRF2 peptide (pink). (B and C) Two corresponding surface representations of KLHL3–WNK4 and KEAP1–NRF2,
with bound peptides shown as yellow ribbons, reveal markedly different binding pockets. Key contact residues are highlighted according to their properties; blue indicates a basic, red indicates polar
and green indicates hydrophobic residues.
KEAP1 Kelch domain, compared with blades II, III and IV for
the KLHL2/3–WNK4 complex. Despite the apparent structural
similarity of the Kelch domain backbones, the binding pockets
bear no resemblance to one another in terms of both 3D shape and
the position of contact residues across the pocket (Figures 4B
and 4C). These differences help to explain the exquisite specificity
of these adaptor proteins for their substrates, which is essential for
ensuring the specific regulation of ubiquitylation, and also clearly
have implications for the development of selective small-molecule
inhibitors of the KEAP1 Kelch domain [48].
Mutations in KEAP1 have also been identified in human
disease, most notably cancers of the lung, breast and gall
bladder [37,49,50]. Parallel to Gordon’s syndrome mutations in
KLHL3, several of the reported KEAP1 mutations directly perturb
the interface with NRF2, whereas others are likely to disrupt the
structural integrity of the Kelch domain fold. Of these, many
are found at the recurring double glycine motif on the second
β-strand of Kelch repeats I, II, III and IV. The double glycine
motif is conserved in KLHL2 and KLHL3 (Figure 2B), but there
are currently no reported Gordon’s syndrome mutations at these
sites. Most described Gordon’s syndrome mutations in KLHL3 are
located either close to the peptide binding site or more randomly
throughout the structure with no recognizable pattern between the
Kelch repeats. It is clear that, despite the broad similarities in
the structural fold of KEAP1 and KLHL2/KLHL3, there are
crucial differences in the way these proteins interact with their
substrates.
The findings described in the present paper provide important
new insights into the regulation of WNK kinases by CRL3KLHL3
and, moreover, shed light on the very diverse mode of interactions
between substrates and their E3 ligases. In the future, it will
be important to determine the contribution of KLHL2 to blood
pressure regulation, to understand if all WNK isoforms are indeed
substrates of CRL3KLHL3 and to elucidate if and how WNK
degradation is regulated by external signals.
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Figure S1 KLHL2–WNK4 peptide complex
(A) Superimposition of the crystal structures of KLHL2–WNK4 (blue with green peptide) and KLHL3–WNK4 (pink with yellow peptide) reveals the similarity between the two complexes. The key
contact residues are labelled (left panel). Multiple conformations are visible for Arg528 and Tyr577 in the KLHL2 structure. His566 and the side chains from Glu559 and Glu560 of WNK4 are traceable in
the KLHL2 structure, but are absent in the KLHL3 structure (right-hand panel). (B) Comparison of the apo (orange, PDB code 2XN4) and WNK4-bound structures of KLHL2 (blue) reveals the rigidity
of the Kelch β-propeller and peptide-binding site. Electron density for the bound peptide is shown on the right-hand panel.
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